Payment overview · 2025
General Payments
$174,543.57
492 reported records · 28 companies
Healthcare provider profile · identity verified
Richard Haddad, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · RED BANK, NJ · NPI 1750382800
Verified facts
What the public records show
CMS Open Payments records show Richard Haddad, MD received $174,543.57 in general payments during 2025 across 492 reported records.
Janssen Biotech, Inc. accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Kevzara, Orencia, Otezla, Rinvoq, Simponi Aria.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Orencia by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEVZARA as an associated drug or biological on 5840 records involving 2002 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kevzara by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REMICADE as an associated drug or biological on 113 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Remicade by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI ARIA as an associated drug or biological on 28612 records involving 8458 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Simponi Aria by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $62,869.38 | 36.0% | 126 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38,887.48 | 22.3% | 83 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28,403.58 | 16.3% | 66 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19,804.06 | 11.3% | 29 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $6,556.88 | 3.8% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $6,545.73 | 3.8% | 25 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $6,433.99 | 3.7% | 26 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $2,675.32 | 1.5% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $414.16 | 0.2% | 24 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $296.81 | 0.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $275.28 | 0.2% | 20 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $206.52 | 0.1% | 8 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $180.29 | 0.1% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $133.12 | 0.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $122.60 | 0.1% | 7 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $113.71 | 0.1% | 7 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $112.16 | 0.1% | 6 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $88.64 | 0.1% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $85.43 | 0.1% | 5 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $78.37 | 0.0% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.06 | 0.0% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $49.19 | 0.0% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $48.64 | 0.0% | 3 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $37.54 | 0.0% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $22.76 | 0.0% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $17.74 | 0.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.40 | 0.0% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $14.73 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $140,182.50 | 63 |
| Travel and Lodging | $15,936.36 | 30 |
| Food and Beverage | $10,954.74 | 394 |
| Consulting Fee | $7,200.00 | 2 |
| Education | $269.97 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $62,850.69 | 125 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $43,898.93 | 67 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $25,581.84 | 53 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $19,804.06 | 29 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $19,094.93 | 27 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13,427.32 | 27 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $6,556.88 | 20 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $6,545.73 | 25 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $2,811.90 | 12 | 2025 |
Source payment records
|
|||||
| Gamifant Normalized: gamifant |
Drug | SOBI, INC | $2,506.50 | 3 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $342.90 | 20 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $296.81 | 6 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $275.28 | 20 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $206.52 | 8 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $199.20 | 16 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $180.29 | 3 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $180.29 | 3 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $180.29 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $147.71 | 13 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $133.12 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $122.60 | 7 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $113.71 | 7 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $112.16 | 6 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $88.64 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $85.85 | 6 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $85.43 | 5 | 2025 |
Source payment records
|
|||||
| ILARIS Normalized: ilaris |
Drug | Novartis Pharmaceuticals Corporation | $71.26 | 4 | 2025 |
Source payment records
|
|||||
| HYRIMOZ Normalized: hyrimoz |
Biological | Sandoz Inc. | $60.12 | 3 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $54.06 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $49.19 | 3 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $48.64 | 3 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $36.14 | 4 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $35.26 | 2 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $31.43 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| JUBBONTI Normalized: jubbonti |
Biological | Sandoz Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $9.84 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $9.84 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $9.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEVZARA kevzara |
2025 | Kevzara | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SIMPONI ARIA simponi aria |
2025 | Simponi Aria | 2024 | 216 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | KEVZARA open payments reported associated product |
CMS Open Payments — General Payments 5840 supporting records · 2002 recipient NPIs · example record 1233195032 |
Kevzara · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | REMICADE open payments reported associated product |
CMS Open Payments — General Payments 113 supporting records · 89 recipient NPIs · example record 1174377572 |
Remicade · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI ARIA open payments reported associated product |
CMS Open Payments — General Payments 28612 supporting records · 8458 recipient NPIs · example record 1174257377 |
Simponi Aria · 2024 Exact normalized brand match · 1 Part D row |
216 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methotrexate | Methotrexate Sodium | 1175 | 355 |
| Prednisone | Prednisone | 1050 | 364 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 891 | 239 |
| Gabapentin | Gabapentin | 544 | 131 |
| Allopurinol | Allopurinol | 393 | 98 |
| Duloxetine Hcl | Duloxetine Hcl | 321 | 89 |
| Meloxicam | Meloxicam | 221 | 82 |
| Simponi Aria | Golimumab | 216 | 48 |
| Tramadol Hcl | Tramadol Hcl | 196 | 43 |
| Sulfasalazine | Sulfasalazine | 191 | 62 |
| Celecoxib | Celecoxib | 183 | 66 |
| Methylprednisolone | Methylprednisolone | 177 | 119 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 173 | 25 |
| Folic Acid | Folic Acid | 144 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 21 |
| Colchicine | Colchicine | 132 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 35 |
| Pregabalin | Pregabalin | 89 | 22 |
| Leflunomide | Leflunomide | 88 | 30 |
| Alprazolam | Alprazolam | 81 | 12 |
| Cimzia (2 Pack) | Certolizumab Pegol | 71 | 13 |
| Enbrel Sureclick | Etanercept | 70 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 33 |
| Trazodone Hcl | Trazodone Hcl | 67 | 14 |
| Otezla | Apremilast | 65 | suppressed |
| Ibuprofen | Ibuprofen | 57 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 44 | suppressed |
| Naproxen | Naproxen | 42 | 13 |
| Diclofenac Sodium Er | Diclofenac Sodium | 40 | 13 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 38 | suppressed |
| Taltz Autoinjector | Ixekizumab | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | 13 |
| Baclofen | Baclofen | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Rayos | Prednisone | 30 | suppressed |
| Rinvoq | Upadacitinib | 29 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Febuxostat | Febuxostat | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Prolia | Denosumab | 22 | 13 |
| Famotidine | Famotidine | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Orencia | Abatacept/Maltose | 20 | suppressed |
| Remicade | Infliximab | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Kevzara | Sarilumab | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Relafen Ds | Nabumetone | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 14 | suppressed |
| Benlysta | Belimumab | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Humira(Cf) | Adalimumab | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Humira | Adalimumab | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 11 | suppressed |
| Humira Pen | Adalimumab | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $174,543.57 · 492 records | Janssen Biotech, Inc. | ACTHAR, Actemra, BENLYSTA, Bimzelx, COSENTYX, ENBREL, EVENITY, GLYCATE, Gamifant, HADLIMA, HYRIMOZ, ILARIS, INJECTAFER, JOURNAVX, JUBBONTI, KEVZARA, KRYSTEXXA, Kineret, LUPKYNIS, NALOCET, OFEV, ORENCIA, OTEZLA, PROLATE, PURIFIED CORTROPHIN GEL, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, RENFLEXIS, REZDIFFRA, RINVOQ, SAPHNELO, SIMPONI ARIA, SKYRIZI, STRENSIQ, TANLOR, TAVNEOS, TONMYA, TREMFYA, Tyvaso, UBRELVY, UPLIZNA, VOQUEZNA, XELJANZ, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error